<DOC>
	<DOCNO>NCT02209727</DOCNO>
	<brief_summary>Study determine maximum tolerate dose ( MTD ) safety profile single-dose administration sibrotuzumab ( 50 mg ) conjugate increase dose 131 I isotope .</brief_summary>
	<brief_title>Single Dose Escalation Study 131I-Sibrotuzumab Patients With Advanced Metastatic Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Evidence advance , nonresectable , and/or metastatic nonsmall cell lung cancer least one previous conventional treatment advance disease Eastern cooperative Oncology Group ( ECOG ) performance status 0 1 Measurable evaluable disease , determine World Health Organization ( WHO ) criteria use standard image modality , include ultrasound , Xray , CT and/or Magnetic Resonance Imaging ( MRI ) . Bone scan and/or antibody scan use determine extent disease Expected survival ≥ 16 week At least 18 year age Platelet count ≥ 100 x 10**9/L Absolute neutrophil count ≥ 2.0 x 10**9/L Aspartate aminotransferase ( AST ) ≤ 3 x upper limit normal &lt; 5 x upper limit normal liver metastasis present Total bilirubin ≤ 2mg/dL Serum creatinine ≤ 2mg/dL Ability provide write informed consent Known brain metastasis Exposure investigational agent within 30 day prior receive scout dose Incomplete recovery surgery incomplete heal incision site evidence infection Treatment cytotoxic chemotherapy , radiation immunosuppressive therapy within 30 day ( 42 day nitrosoureas and/or mitomycin C ) scout infusion . Patients use inhaled corticosteroid consider eligible enrollment Serious illness , i.e. , active infection require antibiotic , bleed disorder serious illness preclude use either 131I sibrotuzumab Women breastfeed pregnant Men woman sexually active unwilling utilize medically acceptable method contraception Hypertrophic skin disease autoimmune disease possibly involve overexpression fibroblast activation protein ( FAP ) , target antibody . These disease include active inflammatory arthritis , cirrhosis , keloid Unstable angina pectoris . Patients prescribed medication control angina pectoris must fix dose least 1 month prior screen eligible trial enrollment Myocardial infarction within 3 month prior screen New York Heart Association ( NYHA ) Heart failure stage III IV , leave ventricular ejection fraction ≤ 40 % Impaired lung function , measure decrease forced expiratory volume one second ( FEV1 ) less 50 % predict normal value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>